TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma

Head and Neck

Volumn 26, Issue 12, 2004, Pages 1069-1083

  Hawthorn, Lesleyann ^a   Stein, Leighton ^a   Varma, Ram ^a   Wiseman, Samuel ^a   Loree, Thom ^a   Tan, DongFeng ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Gene expression alterations; Goiter; Microarray; Papillary thyroid carcinoma

Indexed keywords

BIOLOGICAL MARKER; CELLULAR RETINOIC ACID BINDING PROTEIN 1; SERPIN A; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TREFOIL FACTOR 3; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MALE; NODULAR GOITER; PAPILLOMA; PRIORITY JOURNAL; THYROID CARCINOMA;

ADULT; AGED; ALPHA 1-ANTICHYMOTRYPSIN; BIOPSY, NEEDLE; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; RECEPTORS, RETINOIC ACID; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 10044254396     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20099     Document Type: Article

References (108)

1. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults. Long term followup of 1039 patients conservatively treated at one institution during three decades. Surgery 1998;104:1157-1166.
2. Pierotti MA. Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma. Cancer Letters 2001;166:1-7.
3. Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58:4193-4198.
4. Arscott PL, Stokes T, Myc A, Giordano TJ, Thompson NW, Baker JR Jr. Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:4246-4252.
5. Satta MA, Nanni S, Della Casa S, Pontecorvi A. Molecular biology of thyroid neoplasms. Rays 2000;25:151-161.
6. Hoang-Vu C, Boltze C, Gimm O, et al. Expression of telomerase genes in thyroid carcinoma. Int J Oncol 2002;21:265-272
7. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-713.
8. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. PNAS 2001;98:15044-15049.
9. Wasenius V-M, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-I, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 2003;9:68-75.
10. Sandrini F, Matyakhina L, Sarlis NJ, et al. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A: a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer 2002;35:182-192.
11. Liu RT, Huang CC, You HL, et al. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 2002;21:4830-4837.
12. Collins MT, Sarlis NJ, Merino MJ, et al. Thyroid carcinoma in the McCune-Albright Syndrome: contributory role of activating Gs(alpha) mutations. J Clin Endocrinol Metab 2003;88:4413-4417.
13. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PREN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64.
14. Cetta F, Olschwang S, Petracci M, et al. Genetic alterations in thyroid carcinoma associated with familial adenomatous polyposis: clinical implications and suggestions for early detection. World J Surg 1998;22:1231-1236.
15. Lacour J, Bignalou J, Perez R, Gerard-Marchant R. Papillary epithelioma of the thyroid gland. Apropos of 2 familial cases. Nouv Presse Med 1973;2:2249-2252.
16. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 1995;130:892-897.
17. Takami H, Ozaki O, Ito K. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg 1996;131:676.
18. Burgess JR, Duffield A, Wilkinson SJ, et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocr Metab 1997;82:345-348.
19. McKay JD, Williamson J, Lesueur F, et al. At least three genes account for familial papillary thyroid carcinoma: TCO and MNG1 excluded as susceptibility loci from a large Tasmanian family. Eur J Endocr 1999; 141:122-125.
20. McKay JD, Leseur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001;69: 440-446.
21. Harach HR. Familial nonmedullary thyroid neoplasia. Endocr Pathol 2001;12:97-112.
22. Medeiros-Neto G. Iodine deficiency disorders. In: de Groot LJ, Jameson JL, eds. Endocrinology. Philadelphia: WB Saunders 2000;1529-1539.
23. Brix TH, Hegedüs L. Genetic and environmental factors in the aetiology of simple goiter. Am Med 2000;32: 153-156.
24. Bignell GR, Canzian F, Shayeghi M, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997;61:1123-1130.
25. - symporter. J Clin Endocrinol Metab 1999;84: 3750-3756.
26. Capon F, Tacconelli A, Giardina E, et al. Mapping a dominant form of multinodular goiter to chromosome Xp22. Am J Hum Genet 2000;67:1004-1007.
27. Abramowicz MJ, Tarkovnik HM, Varela V, et al. Identification of a mutation in the coding sequence of the human thyroid peroxidase gene causing congenital goiter. J Clin Invest 1992;90:1200-1204.
28. Ieri T, Cocheaux P, Targovnik HM, et al. A 3′ splice site mutation in the thyroglobulin gene responsible for congenital goiter with hypothyroidism. J Clin Invest 1991; 88:1901-1905.
29. Corral J, Martin C, Perez R, et al. Thyroglobulin gene point mutation associated with non-endemic simple goiter. Lancet 1993;341:462-464.
30. van Sande J, Parma J, Tonacchera M, Swillens S, Dumont J, Vassart G. Genetic basis of endocrine disease: somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 1995; 80:2577-2585.
31. - symporter. Nat Genet 1997;16:124-125.
32. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-2492.
33. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
34. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998;1378:F21-F59.
35. Belfiore A, LaRosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992; 93:363-369.
36. Pelizzo MR, Bernante P, Toniato A, Fassina A. Frequency of thyroid carcinoma in a recent series of 539 consecutive thyroidectomies for multinodular goiter. Tumori 1997;83:653-655.
37. Tollin SR, Mery GM, Jelveh N, et al. The use of fine-needle aspiration biopsy under ultrasound guidance to assess the risk of malignancy in patients with a multinodular goiter. Thyroid 2000;10:235-241.
38. Gogas JG, Skalkeas GD. Thyroid nodules and thyroid carcinoma. Int Surg 1975;60:534-535.
39. Ardito G, Mantovani M, Vincenzoni C, et al. Hyperthyroidism and carcinoma of the thyroid gland. Ann Ital Chir 1997;68:23-27.
40. Nicolosi A, Addis E, Calo PG, Tarquini A. Hyperthyroidism and cancer of the thyroid. Minerva Chir 1994;49: 491-495.
41. Valdina EA. Nodular goiter and thyroid cancer. Vestn Khir Im I I Grek 1997;156:23-26.
42. Dumitriu L, Mogos I, Tasca C. Morphologic relationships between thyroid carcinoma and associated thyroid lesions in thyroidectomized patients. Comparison between 60 malignancies and 40 non-malignant goiters. Endocrinologie 1987;25:25-39.
43. McCall A, Jarosz H, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in solitary cold nodules and in multinodular goiters. Surgery 1986;100: 1128-1132.
44. Sachmechi I, Miller E, Varatharajah R, Chernys A, Carroll Z, Kissin E, Rosner F. Thyroid carcinoma in single cold nodules and in cold nodules of multinodular goiters. Endocr Pract 2000;6:5-7.
45. Khurana KK, Labrador E, Izquierdo R, Mesonero CE, Pisharodi LR. The role of fine-needle aspiration biopsy in the management of thyroid nodules in children, adolescents, and young adults: a multi-institutional study. Thyroid 1999;9:383-386.
46. Przybylik-Mazurek E, Szybinski Z. Biological risk factors for differentiated thyroid cancer. Wiad Lek 2001; 54(Suppl 1):157-162.
47. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868.
48. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001;2:RESEARCH0032.
49. Liu G, Loraine AE, Shigeta R, et al. NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res 2003;31: 82-86.
50. LiVolsi VA. Surgical pathology of the thyroid. Vol. 5, Philadelphia, WB Saunders 1990.
51. Tan D, Kirley S, Li Q, Ramnath N, Slocum HK, Brooks JS, Wu CL, Zukenberg LR. Loss of Cables protein expression in human non-small cell lung cancer: a tissue microarray study. Hum Pathol 2003;34:143-149.
52. Poblete MT, Nualart F, del Pozo M, Perez JA, Figueroa CD. Alpha 1-antitrypsin expression in human thyroid papillary carcinoma. Am J Surg Pathol 1996;20: 956-963.
53. Lai ML, Rizzo N, Liguori C, Zucca G, Faa G. Alpha-1-antichymotrypsin immunoreactivity in papillary carcinoma of the thyroid gland. Histopathology 1998;33: 332-336.
54. Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 2001;438:121-128.
55. Korem S, Resnick MB, Kraiem Z. Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. J Clin Endocrinol Metab 1999;84:3322-3327.
56. Shi Y, Parhar RS, Zou M, et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma. Br J Cancer 1999; 79:1234-1239.
57. Kraiem Z, Korem S. Matrix metalloproteinases and the thyroid. Thyroid 2000;10:1061-1069.
58. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepien H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 2002; 12:655-662.
59. Patel A, Straight AM, Mann H, et al. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents. J Endocrinol Invest 2002;25:403-408.
60. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-2484.
61. Xu XC, Ni-Naggar AK, Lotan R. Differential expression of galectin 1 and galectin-3 in thyroid tumors: potential diagnostic implications. Am J Pathol 1995;147:815-822.
62. Niedobitek C, Niedobitek F, Lindenberg G, et al. Expression of galectin-3 in thyroid gland and follicular cell tumors of the thyroid. A critical study of its possible role in preoperative differential diagnosis. Pathologe 2001;22: 205-213.
63. Bartolazzi A, Gasbarri A, Papotti M, et al. Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-1650.
64. Yoshii T, Inohara H, Takenaka Y, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001;18:787-792.
65. Fiorella PD, Napoli JL. Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. J Biol Chem 1991; 266:16572-16579.
66. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J 2000;348:481-495.
67. Simon K, Köhrle J, Reiners C, et al. Redifferentiation therapy with retinoids- a therapeutic option in advanced follicular and papillary thyroid carcinoma. World J Surg 1989;22:569-574.
68. Schmutzler C, Brtko J, Bienert K, Köhrle J. Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived from them. Exptl Clin Endo Diab 1998;104(Suppl):16-19.
69. Grüning T, Tiepolt C, Zöphel K, Bredow J, Kropp J, Frank W. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise? Eur J Endo 2003;148: 395-402.
70. Liu D, el-Hariry I, Karayiannakis AJ, et al. Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 1997;77: 557-563.
71. May FEB, Westley BRW. Trefoil proteins: their role in normal and malignant cells. J Pathol 1997;183:2-7.
72. Malik HS, Burke WD, Eickbush TH. The age and evolution of non-LTR retrotransposable elements. Mol Biol Evol 1999;16:793-805.
73. Brosius J. RNAs from all categories generate retrosequences that may be exapted as novel genes or regulatory elements. Gene 1999;238:115-134.
74. Raphael SJ, McKeown-Eyssen G, Asa SL. High-molecular weight cytokeratin and cytokeratin 19 in the diagnosis of thyroid tumors. Mod Pathol 1994;7:295-300.
75. Miettinen M, Kovatich AJ, Karkkainen P. Keratin subsets in papillary and follicular thyroid lesions. Virchows Arch 1997;431:407-413.
76. Barbacid M, Lamballe F, Pulido D, Klein R. The trk family of tyrosine protein kinase receptors. Biochim Biophys Acta 1991;1072:115-127.
77. Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A 1992;89:1616-1620.
78. Gimm O, Dziema H, Brown J, et al. Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. Int J Cancer 2001;92:70-74.
79. Wood WM, Sarapura VD, Dowding JM, et al. Early gene expression changes preceding thyroid hormone-induced involution of a thyrotrope tumor. Endocrinology 2002; 143:347-359.
80. Backeljauw PF, Dai Z, Clemmons DR, D'Ercole AJ. Synthesis and regulation of insulin-like growth factor binding protein-5 in FRTL-5 cells. Endocrinology 1993; 132:1677-1681.
81. Eggo MC, King WJ, Black EG, Sheppard MC. Functional human thyroid cells and their insuslin-like growth factor-binding proteins; regulation by thyrotropin, cyclic 3′,5′ adenosine monophosphate, and growth factors. J Clin Endocrinol Metab 1996;81:3056-3062.
82. Miranda E, Vizoso F, Martin M, et al. Apolipoprotein expression in cutaneous malignant melanoma. J Surg Oncol 2000;83:99-105.
83. Califano D, Monaco C, Santelli G, et al. Thymosin β-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res 1998;58:823-828.
84. Takano T, Hasegawa Y, Miyauchi A, et al. Quantitative analysis of thymosin beta-10 messenger RNA in thyroid carcinomas. Jpn J Clin Oncol 2002;32:229-232.
85. Santelli G, Bartoli PC, Giuliano A, et al. Thymosin beta-10 protein synthesis suppression reduces the growth of human thyroid carcinoma cells in semisolid medium. Thyroid 2002;12:765-772.
86. Qian N, Frank D, O'Keefe D, et al. The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. Hum Mol Genet 1997;6:2021-2029.
87. Muller S, van den Boom D, Zirkel D, et al. Retention of imprinting of the human apoptosis-related gene TSSC3 in human brain tumors. Hum Mol Genet 2000;9:757-763.
88. Masters BA, Kelly EJ, Quaife CJ, Brinster RL, Palmiter RD. Targeted disruption of metallothionein I and II genes increases sensitivity to cadmium. Proc Nat Acad Sci U S A 1994;91:584-588.
89. Karin M, Haslinger A, Holtgreve H, et al. Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-II(A) gene. Nature 1984;308:513-519.
90. Kasahara K, Fujiwara Y, Nishio K, et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1999; 51:3237-3242.
91. Theocharis SE, Margeli AP, Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 2003;3:162-169.
92. Nartey N, Cherian MG, Banerjiee D. Immunohistochemical localization of metallothionein in human thyroid tumors. Am J Pathol 129:177-182.
93. Cherian MG. The significance of the nuclear and cytoplasmic localization of metallothionein in human liver and tumor cells. Environ Health Perspect 1994; Suppl 3:131-135.
94. Hasskarl J, Munger K. Id proteins - tumor markers or oncogenes? Cancer Biol Ther 2002;1:91-96.
95. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Overexpression of ID-1 in prostate cancer. J Urol 2002;167: 2598-2602.
96. Schoppmann SF, Schindl M, Bayer G, et al. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer 2002;104: 677-682.
97. Schindl M, Schoppmann SF, Strobel T, et al. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 2003;9:779-785.
98. Wang X, Xu K, Ling MT, et al. Evidence of increased Id-1 expression and its role in cell proliferation in nasopharyngeal carcinoma cells. Mol Carcinog 2002;35: 42-49.
99. Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B, Birner P. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res 2001;61:5703-5706.
100. Maruyama H, Kleeff J, Wildi S, et al. Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol 1999;155: 815-822.
101. Kebebew E, Treseler PA, Duh QY, Clark OH. The helix-loop transcrioption factor, Id-1, is overexpressed in medullary thyroid cancer. Surgery 2000;128:952-957.
102. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-156.
103. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 2003;104:735-744.
104. Eszlinger M, Krohn K, Paschke R, Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J Clin Endocrinol Metab 2001;86: 4834-4842.
105. Pauws E, Moreno JC, Tijssen M, Baas F, De Vijlder JJM, Ris-Stallpers C. Serial analysis of gene expression as a tool to assess the human thyroid expression profile and to identify novel thyroidal genes. J Clin Endocrinol Metab 2000;85:1923-1927.
106. Takano T, Hasegawa Y, Matsuzuka F, et al. Gene expression profiles in thyroid carcinomas. Br J Cancer 2000;83:1495-1502.
107. Yamazaki K, Yamada E, Kanaji Y, et al. Genes regulated by thyrotropin and iodide in cultured human thyroid follicles: analysis by cDNA microarray. Thyroid 2003; 13:149-158.
108. Boltze C, Schneider-Stock R, Quednow C, et al. Proteome analysis odentified maspin as a special feature of papillary thyroid carcinoma. Int J Oncol 2003;23:1323-1328.